(69 days)
Not Found
Not Found
No
The summary describes a standard enzyme immunoassay for drug detection and does not mention any AI or ML components.
No
The device is an in vitro diagnostic assay used to detect propoxyphene in urine, not to treat a disease or condition.
Yes
The device is an immunoassay intended for qualitative and semiquantitative analysis of propoxyphene in human urine, which provides a preliminary analytical test result for drugs-of-abuse. This type of analysis falls under the definition of a diagnostic device.
No
The device description explicitly states it is a "homogenous enzyme assay," which is a chemical reagent-based test, not a software-only device. It is intended for use with chemistry analyzers, implying hardware interaction.
Based on the provided text, the device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states the assay is for the "qualitative and semiquantitative analyses of propoxyphene in human urine." This involves testing a biological sample (urine) in vitro (outside the body) to provide information about a person's health status (presence of propoxyphene).
- Device Description: The description confirms it's a "homogenous enzyme assay intended for use in qualitative and semiquantitative analysis of propoxyphene in urine." This further reinforces its function as an in vitro test.
- Performance Studies: The performance studies describe testing the assay's performance using biological samples (human urine) and comparing results to a predicate method, which is typical for IVD devices.
The core function of analyzing a biological sample in vitro to provide diagnostic information (even if preliminary) clearly places this device in the category of an In Vitro Diagnostic.
N/A
Intended Use / Indications for Use
Syva Emit® II Plus Propoxyphene Assay is a homogeneous enzyme immunoassay. The assay is intended for use in the qualitative and semiquantitative analysis of propoxyphene in human urine.
The Emit® II Plus Propoxyphene Assay is a homogeneous drugs-of-abuse enzyme immunoassay with a 300 ng/mL cutoff. The assay is intended for use in the qualitative and semiquantitative analyses of propoxyphene in human urine. Emit® II Plus assays are designed for use with a number of chemistry analyzers.
The Emit® II Plus Propoxyphene Assay provides only a preliminary analytical test result. A more specific alternative chemical method must be used to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Other chemical confirmation methods are available. Clinical consideration and professional judgment should be applied to any drug-of-abuse test result, particularly when preliminary positive results are used.
Product codes (comma separated list FDA assigned to the subject device)
JXN
Device Description
This 510(k) Summary of Safety and Effectiveness is being submitted in accordance with the requirements of SMDA 1990.
The Syva Emit® II Plus Propoxyphene Assay is a homogenous enzyme assay intended for use in qualitative and semiquantitative analysis of propoxyphene in urine.
The Syva Emit® II Plus Propoxyphene Assay has been found to be equivalent to the predicate device: Syva Emit® II Propoxyphene Assay with regard to intended use, assay sample, and overall performance characteristics.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Comparative Analysis: The Syva Emit® II Plus Propoxyphene Assay showed excellent correlation to the predicate method. The comparative analysis to the predicate method resulted in 98% agreement in finding samples negative and positive.
Spiked Sample Recovery: In qualitative spike analysis, the Emit® II Plus Propoxyphene Assay using a 300 ng/mL cutoff correctly identified the spiked specimens as being negative and positive. Known levels of propoxyphene, spiked at levels less than or equal to minus 25% of the cutoff (0 to 225 ng/mL) were consistently distinguished as negative and those spiked at levels greater than or equal to plus 25% of the cutoff (375 to 1500 ng/mL) were consistently distinguished as positive.
The semiquantitative attribute was assessed by determining the accuracy of recovery for analyte-spiked samples by the Emit® II Plus Propoxyphene Assay. Negative human urine specimens were spiked with concentrations of propoxyphene at levels throughout the semiquantitative range of 75 to 450 ng/mL. For each known concentration, drug recovery was calculated using the average concentration obtained by the Emit® II Plus Propoxyphene Assay. Within this range, recovery ranged up to ± 13% of nominal concentrations of spiked analyte.
Precision: A precision study was performed using Syva Emit® II Plus Propoxyphene Assay in both the qualitative and semiqualitative modes. Acceptable within-run and total precision statistics for both the qualitative and semiquantitative assays were observed.
Qualitative results, determined from rates for controls and cutoff calibrator, demonstrated within-run precision with coefficients of variation (CV) of 0.4% and total precision with CV ranging from 0.7 - 0.8%.
Semiquantitative results, determined from concentrations for controls and cutoff calibrator, demonstrated within-run precision with CV ranging from 1.6 - 2.2% and total precision with CV ranging from 3.0 - 3.8%.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Sensitivity: The sensitivity level of the Emit® II Plus Propoxyphene Assay is less than 60 ng/mL. This level represents the lowest concentration of propoxyphene that can be distinguished from 0 ng/mL with a confidence level of 95%.
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Not Found
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.3700 Propoxyphene test system.
(a)
Identification. A propoxyphene test system is a device intended to measure propoxyphene, a pain-relieving drug, in serum, plasma, and urine. Measurements obtained by this device are used in the diagnosis and treatment of propoxyphene use or overdose or in monitoring levels of propoxyphene to ensure appropriate therapy.(b)
Classification. Class II (special controls). A propoxyphene test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (e.g., programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
0
FEB 1 2000
Image /page/0/Picture/1 description: The image shows a sequence of characters and numbers. The sequence starts with the letter 'K', followed by the numbers '993981'. The characters are written in a handwritten style, with varying stroke thicknesses. The overall appearance suggests a serial number or identification code.
510(k) SUMMARY OF SAFETY AND EFFECTIVENESS For Syva Emit® II Plus Propoxyphene Assay
1. Manufacturer and Contact Information:
| Manufacturer: | Syva Company – Dade Behring Inc.
3403 Yerba Buena Rd.
P.O. Box 49013
San Jose, CA 95161-9013 |
| --------------- | ------------------------------------------------------------------------------------------------------- |
|---|
Contact Information: Paul Rogers Syva Company 3403 Yerba Buena Road San Jose, CA 95161-9013 Tel: 408-239-2000
2. Device Classification Name:
The Clinical Chemistry and Clinical Toxicology Devices Panel have classified "Propoxyphene Test System" as Class II.
3. Intended Use:
Syva Emit® II Plus Propoxyphene Assay is a homogeneous enzyme immunoassay. The assay is intended for use in the qualitative and semiquantitative analysis of propoxyphene in human urine.
4. Device Description and Characteristics:
This 510(k) Summary of Safety and Effectiveness is being submitted in accordance with the requirements of SMDA 1990.
The Syva Emit® II Plus Propoxyphene Assay is a homogenous enzyme assay intended for use in qualitative and semiquantitative analysis of propoxyphene in urine.
The Syva Emit® II Plus Propoxyphene Assay has been found to be equivalent to the predicate device: Syva Emit® II Propoxyphene Assay with regard to intended use, assay sample, and overall performance characteristics.
Comparative Analysis: The Syva Emit® II Plus Propoxyphene Assay showed excellent correlation to the predicate method. The comparative analysis to the predicate method resulted in 98% agreement in finding samples negative and positive.
1
510(k) SUMMARY OF SAFETY AND EFFECTIVENESS For Syva Emit Propoxyphene Assay (cont.)
Spiked Sample Recovery: In qualitative spike analysis, the Emit® II Plus Propoxyphene Assay using a 300 ng/mL cutoff correctly identified the spiked specimens as being negative and positive. Known levels of propoxyphene, spiked at levels less than or equal to minus 25% of the cutoff (0 to 225 ng/mL) were consistently distinguished as negative and those spiked at levels greater than or equal to plus 25% of the cutoff (375 to 1500 ng/mL) were consistently distinguished as positive.
The semiquantitative attribute was assessed by determining the accuracy of recovery for analyte-spiked samples by the Emit® II Plus Propoxyphene Assay. Negative human urine specimens were spiked with concentrations of propoxyphene at levels throughout the semiquantitative range of 75 to 450 ng/mL. For each known concentration, drug recovery was calculated using the average concentration obtained by the Emit® II Plus Propoxyphene Assay. Within this range, recovery ranged up to ± 13% of nominal concentrations of spiked analyte.
Precision: A precision study was performed using Syva Emit® II Plus Propoxyphene Assay in both the qualitative and semiqualitative modes. Acceptable within-run and total precision statistics for both the qualitative and semiquantitative assays were observed.
Qualitative results, determined from rates for controls and cutoff calibrator, demonstrated within-run precision with coefficients of variation (CV) of 0.4% and total precision with CV ranging from 0.7 - 0.8%.
Semiquantitative results, determined from concentrations for controls and cutoff calibrator, demonstrated within-run precision with CV ranging from 1.6 - 2.2% and total precision with CV ranging from 3.0 - 3.8%.
Sensitivity: The sensitivity level of the Emit® II Plus Propoxyphene Assay is less than 60 ng/mL. This level represents the lowest concentration of propoxyphene that can be distinguished from 0 ng/mL with a confidence level of 95%.
5. Substantial Equivalence:
In conclusion, Syva Company - Dade Behring Inc. considers the Syva Emit® II Plus Propoxyphene Assay to be substantially equivalent to the Emit® II Propoxyphene Assay with regard to intended use, assay sample, and overall performance characteristics.
2
Image /page/2/Picture/1 description: The image shows the logo for the Department of Health & Human Services (HHS). The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized symbol resembling a caduceus or a representation of human figures.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
1 2000 FEB
Mr. Paul L. Rogers Jr. Senior Manager, Regulatory Affairs Syva Company - Dade Behring Inc. P.O. Box 49013 3403 Yerba Buena Road San Jose, California 95161-9013
Re: K993981
Trade Name: Syva Emit® II Plus Propoxyphene Assay Regulatory Class: II Product Code: JXN Dated: November 23, 1999 Received: November 24, 1999
Dear Mr. Rogers:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (OS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
3
Page 2
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Sutman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Device Name: Syva Emit® II Plus Propoxyphene Assay
Indications for Use:
The Emit® II Plus Propoxyphene Assay is a homogeneous drugs-of-abuse enzyme immunoassay with a 300 ng/mL cutoff. The assay is intended for use in the qualitative and semiquantitative analyses of propoxyphene in human urine. Emit® II Plus assays are designed for use with a number of chemistry analyzers.
The Emit® II Plus Propoxyphene Assay provides only a preliminary analytical test result. A more specific alternative chemical method must be used to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Other chemical confirmation methods are available. Clinical consideration and professional judgment should be applied to any drug-of-abuse test result, particularly when preliminary positive results are used.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
| Concurrence of CDRH, Office of Device Evaluation (ODE) | ||
|---|---|---|
| P. Beinhardt for Dig. Cooper | ||
| (Division Sign-Off) | ||
| Division of Clinical Laboratory Services | ||
| 510(k) Number: K992981 | ||
| Prescription Use | ||
| (Per 21 CFR 801.109) | OR | Over-The-Counter Use |
| (Optional Format 1-2-96) |